期刊文献+

吉西他滨联合调强放疗治疗局部晚期胰腺癌21例 被引量:8

Intensity Modulated Radiotherapy Combined with Gemcitabine Chemotherapy for 21 cases with Locally Advanced Pancreatic Cance
原文传递
导出
摘要 [目的]观察吉西他滨+顺铂联合调强放疗(IMRT)序贯放化疗治疗局部晚期胰腺癌的疗效及安全性。[方法]21例局部晚期胰腺癌患者采用吉西他滨+顺铂3周方案化疗后局部病灶行IMRT治疗。GP方案(吉西他滨1000mg/m2d1.8+顺铂80mg/m2d1静脉滴注),21d为1个周期,化疗2~4个周期后.给予胰腺局部病灶IMRT照射剂量6MVX线DT60~66Gy,2Gy/次,1次/d,5d/周。[结果]21例患者全部完成放化疗计划,胰腺癌原发灶完全缓解(CR)为4.8%(1/21),部分缓解率(PR)为28.6%(6/21),疾病稳定(SD)为42.9%(9/21),疾病进展(PD)23.8%(5/21)。1年及2年生存率分别为38.1%和19.0%。疼痛缓解率为90.5%(19/211。生活质量明显改善。白细胞下降发生率为85.7%(18/21),对症治疗可恢复,无治疗相关死亡事件发生。[结论]吉西他滨+顺铂联合IMRT序贯放化疗治疗局部晚期胰腺癌能明显提高患者的生活质量和生存期,不良反应能为大多数患者耐受,是治疗局部晚期胰腺癌的可选方法。
出处 《肿瘤学杂志》 CAS 2016年第1期76-78,共3页 Journal of Chinese Oncology
  • 相关文献

参考文献17

  • 1Kim RI ,Saif MW. Is there an optimal neoadjuvant thera- py for locally advanced pancreatic cancer[J].JOP,2007,8 (3) : 279-288.
  • 2New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009,45 (2) : 228-247.
  • 3Oxberry S,Middleton V,Bennett M.What does a good quality of life for cancer patients mean on a numerical rat- ing scale?[J]. J Clin Oncol, 2005,17(2):129.
  • 4Trotti A, Colevas AD, Setser A. CTCAE v3.0 : development of a comprehensive grading system for the adverse effects [J].Semin Radiat Onco1,2003,3 : 176-181.
  • 5Sohn TA,Yeo CJ,Canmeron JL,et al. Resected adenocar- cinoma of the pancreas-616 patients :results,outcomes, and prognostic indicators [J]. J Gastrointest Surg,2000,4 (6) : 567-579.
  • 6Huguet F1,Andre T,Hammel P,et al.Impact of chemora- diotherapy after disease control with chemotherapy in local- ly advanced pancreatic adenocarcinoma in GERCOR phase I1 and 111 studies[J].J Clin Oncol,2007,25(3):326-331.
  • 7Spalding AC ,Jee KW,Vineberg K,et al. Potential for dose- escalation and reduction of risk in pancreatic cancer using IMRT optimization with lexicographic ordering and gEUD-based cost functions[J].Med Phys, 2007,34(2) :521-529.
  • 8Burris HA,Moore MJ,Andersen J. Improvements in sur- vival and clinical benefit with gemcitabine first-line thera- py for patients with advanced pancreas cancer:a random- ized trial[J]. J Clin Oncol, 1997,15(6) : 2403-2413.
  • 9Muhammad WS. U.S.Food and Drug Administration ap- proves paclitaxel protein-bound particlesin combination with gemcitabine as first-line treatment of patients with metastatic pancreatic cancer [J].J Pancreas (Online), 2013,14(6):686-688.
  • 10Gourgou-Bourgade S,Bascoul-Mollevi C,Desseigne F,et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic can- cer: results from the PRODIGE 4/ACCORD 11 random- ized trial[J].J Clin Oncol, 2013,31 (1) : 23-29.

二级参考文献24

  • 1Burris H A 3rd,Moore M J,Andersen J,et al.Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer:a randomized trial[J].J Clin Oncol,1997,15(6):2403-2413.
  • 2Storniolo A M,Enas N H,Brown C A,et al.An investigational new drug treatment program for patients with gemcitabine:results for over 3000 patients with pancreatic carcinoma[J].Cancer,1999,85(6):1261-1268.
  • 3Philip P A,Zalupski M M,Vaitkevicius V K,et al.Phase Ⅱ study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma[J].Cancer,2001,92(3):569-577.
  • 4Scheithauer W,Schull B,Ulrich-Pur H,et al.Biweekly highdose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma:a randomized phase Ⅱ trial[J].Ann Oncol,2003,14(1):97-104.
  • 5Alberts S R,Townley P M,Goldberg R M,et al.Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma:a North Central Cancer Treatment Group phase Ⅱ study[J].Ann Oncol,2003,14(4):580-585.
  • 6Berlin J D,Catalano P,Thomas J P,et al.Phase Ⅲ study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma:Eastern Cooperative Oncology Group Trial E2297[J].J Clin Oncol,2002,20(15):3270-3275.
  • 7Colucci G,Giuliani F,Gebbia V,et al.Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma:a prospective,randomized phase Ⅲ study of the Gruppo Oncologia dell'Italia Meridionale[J].Cancer,2002,94(4):902-910.
  • 8Louvet C,Labianca R,Hammel P,et al.Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer:results of a GERCOR and GISCAD phase Ⅲ trial[J].J Clin Oncol,2005,23(15):3509-3516.
  • 9Herrmann R,Bodoky G,Ruhstaller T,et al.Gemcitabine plus capecitabine versus gemcitabine alone in advanced pancreatic cancer:a randomized,multicenter,phase Ⅲ trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group[J].J Clin Oncol,2007,25 (16):2212-2217.
  • 10Nitecki SS,Sarr MG,Colby TV,et al.Long-term survival after resection for ductal adenocarcinoma of the pancreas.Is it really improving?[J].Ann Surg,1995,221(1):59-66.

共引文献22

同被引文献60

引证文献8

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部